Alzheimer Disease Clinical Trials in New York, New York

11 studies are recruiting for alzheimer disease in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

   This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P…

   Stage

   Phase 2

   Ages

   55 to 80

   Site

   Adams Clinic Harlem, New York, New York

   Locations

   38 in total

   Run by

   Lighthouse Pharmaceuticals, Inc.

   See if you can join NCT06847321 on ClinicalTrials.gov

2. Early Age-Related Hearing Loss Investigation (EARHLI)

   Early Age-Related Hearing Loss Investigation (EARHLI) is a single site study that will randomize late middle age adults to either a hearing intervention (including hearing aids) or a health education intervention. Participants will be followed for 1 year. This study will provide information on redu…

   Stage

   Not phased

   Ages

   55 to 75

   Site

   Columbia University Medical Center, New York, New York

   Run by

   Columbia University

   See if you can join NCT06174038 on ClinicalTrials.gov

3. Autoimmune Features of Neurodegenerative Disorders

   This study is being conducted to better understand the role of inflammation in Parkinson's disease (PD) and Alzheimer's disease (AD). The investigators plan to recruit 30 PD, 30 AD/Amnestic Mild Cognitive Impairment (aMCI), and 60 age matched healthy controls in this study to study the role of immu…

   Stage

   Not phased

   Ages

   55 to 90

   Site

   Columbia University Medical Center, New York, New York

   Run by

   Columbia University

   See if you can join NCT04239079 on ClinicalTrials.gov

4. Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

   The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). F…

   Stage

   Phase 2

   Ages

   50 and older

   Site

   Columbia University Irving Medical Center, New York, New York

   Run by

   Columbia University

   See if you can join NCT04576793 on ClinicalTrials.gov

5. Clinical Trial on Agitation in Alzheimer's Dementia

   The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.

   Stage

   Phase 2

   Ages

   60 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   31 in total

   Run by

   IGC Pharma, LLC

   See if you can join NCT05543681 on ClinicalTrials.gov

6. Late Onset Alzheimer's Disease

   The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to…

   Stage

   Not phased

   Ages

   55 and older

   Site

   Columbia University Irving Medical Center, New York, New York

   Locations

   12 in total

   Run by

   Columbia University

   See if you can join NCT05010603 on ClinicalTrials.gov

7. Aβ Dynamics in LLMD

   This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and as…

   Stage

   Phase 4

   Ages

   60 and older

   Site

   NYU Langone Health, New York, New York

   Locations

   2 in total

   Run by

   NYU Langone Health

   See if you can join NCT05004987 on ClinicalTrials.gov

8. Evaluating the Efficacy of the Pain Identification and Communication Toolkit

   This study will evaluate the Pain Identification and Communication Toolkit (PICT), a multicomponent intervention for caregivers of people with Alzheimer's disease and related dementias (ADRD). PICT provides training in observational pain assessment and coaching in effective pain communication techn…

   Stage

   Not phased

   Ages

   21 and older

   Site

   Weill Cornell Medicine, New York, New York

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT06168604 on ClinicalTrials.gov

9. ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

   The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

   Stage

   Not phased

   Ages

   50 to 85

   Site

   Weill Cornell Medicine, New York, New York

   Locations

   10 in total

   Run by

   InSightec

   See if you can join NCT03671889 on ClinicalTrials.gov

10. NYSCF Scientific Discovery Biobank

    The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store th…

    Stage

    Not phased

    Ages

    0 and older

    Site

    New York Stem Cell Foundation Research Institute, New York, New York

    Run by

    New York Stem Cell Foundation Research Institute

    See if you can join NCT06203106 on ClinicalTrials.gov

11. Triage Survey for Neurology Research Eligibility

    TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Berman Clinical, New York, New York

    Locations

    3 in total

    Run by

    Adams Clinical

    See if you can join NCT06104852 on ClinicalTrials.gov